Clinical Observations on Viomycin Sulphate in the Treatment of Tuberculosis
1) Viomycin in doses of 2 grams twice weekly combined with 12 grams of PAS daily is of slight toxicity. 2) Tinnitus may be expected to occur. Allergic symptoms have not been a major problem. Auditory nerve damage of a serious degree is not frequent. 3) Streptomycin resistant organisms are affected b...
Gespeichert in:
| Veröffentlicht in: | Chest 1953-12, Vol.24 (6), p.591-600 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 600 |
|---|---|
| container_issue | 6 |
| container_start_page | 591 |
| container_title | Chest |
| container_volume | 24 |
| creator | HACKNEY, R L KING, E Q MARSHALL, E E HARDEN, K A PAYNE, H M |
| description | 1) Viomycin in doses of 2 grams twice weekly combined with 12 grams of PAS daily is of slight toxicity.
2) Tinnitus may be expected to occur. Allergic symptoms have not been a major problem. Auditory nerve damage of a serious
degree is not frequent.
3) Streptomycin resistant organisms are affected by viomycin and patients having such organisms improve under intermittent
viomycin treatment.
4) Bacterial resistance to viomycin did not develop to a significant degree among patients treated for six months.
5) Clinical and x-ray improvement is more striking in streptomycin-PAS treated patients, however, the effectiveness of viomycin-PAS
is definite and demonstrable.
6) The clinical use of viomycin is feasible in the presence of streptomycin resistant organisms, and allergic sensitivity
to streptomycin. Its use with newer antimicrobials should be explored. |
| doi_str_mv | 10.1378/chest.24.6.591 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_75381678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75381678</sourcerecordid><originalsourceid>FETCH-LOGICAL-h248t-d01ff661c2372460eb97635617162f478abf5c6eab7075c4b071338ccd14547b3</originalsourceid><addsrcrecordid>eNo1kD1PwzAYhC0EoqWwMiJPbAl2_JWMqOJLIHWgsFq26xBXTlzsBNR_j0Vheu-VHp3uDoBLjEpMRH1jOpvGsqIlL1mDj8AcNwQXhFFyDOYI4aogvKlm4CylLco_bvgpmGGCkWCMz8Hz0rvBGeXhSicbv9TowpBgGOC7C_3euAG-Tn7XqdHCrMfOwnW0auztMMLQwvWkbTSTD8mlc3DSKp_sxd9dgLf7u_XysXhZPTwtb1-KrqL1WGwQblvOsamIqChHVjeCE8axwLxqqaiVbpnhVmmRQxqqkcCE1MZsMGVUaLIA1wffXQyfU-4ve5eM9V4NNkxJCkZqzEWdwas_cNK93chddL2Ke_lfPwPlAejcR_ftopWpV95nnMjfZbdhioPyFZVc5n3JD8vDbRM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75381678</pqid></control><display><type>article</type><title>Clinical Observations on Viomycin Sulphate in the Treatment of Tuberculosis</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>HACKNEY, R L ; KING, E Q ; MARSHALL, E E ; HARDEN, K A ; PAYNE, H M</creator><creatorcontrib>HACKNEY, R L ; KING, E Q ; MARSHALL, E E ; HARDEN, K A ; PAYNE, H M</creatorcontrib><description>1) Viomycin in doses of 2 grams twice weekly combined with 12 grams of PAS daily is of slight toxicity.
2) Tinnitus may be expected to occur. Allergic symptoms have not been a major problem. Auditory nerve damage of a serious
degree is not frequent.
3) Streptomycin resistant organisms are affected by viomycin and patients having such organisms improve under intermittent
viomycin treatment.
4) Bacterial resistance to viomycin did not develop to a significant degree among patients treated for six months.
5) Clinical and x-ray improvement is more striking in streptomycin-PAS treated patients, however, the effectiveness of viomycin-PAS
is definite and demonstrable.
6) The clinical use of viomycin is feasible in the presence of streptomycin resistant organisms, and allergic sensitivity
to streptomycin. Its use with newer antimicrobials should be explored.</description><identifier>ISSN: 0012-3692</identifier><identifier>ISSN: 0096-0217</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.24.6.591</identifier><identifier>PMID: 13107556</identifier><language>eng</language><publisher>United States: American College of Chest Physicians</publisher><subject>Aminosalicylic Acid - therapeutic use ; Antitubercular Agents ; Old Medline ; Sulfates ; Tuberculosis ; Tuberculosis, Pulmonary - therapy ; Viomycin - therapeutic use</subject><ispartof>Chest, 1953-12, Vol.24 (6), p.591-600</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/13107556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HACKNEY, R L</creatorcontrib><creatorcontrib>KING, E Q</creatorcontrib><creatorcontrib>MARSHALL, E E</creatorcontrib><creatorcontrib>HARDEN, K A</creatorcontrib><creatorcontrib>PAYNE, H M</creatorcontrib><title>Clinical Observations on Viomycin Sulphate in the Treatment of Tuberculosis</title><title>Chest</title><addtitle>Dis Chest</addtitle><description>1) Viomycin in doses of 2 grams twice weekly combined with 12 grams of PAS daily is of slight toxicity.
2) Tinnitus may be expected to occur. Allergic symptoms have not been a major problem. Auditory nerve damage of a serious
degree is not frequent.
3) Streptomycin resistant organisms are affected by viomycin and patients having such organisms improve under intermittent
viomycin treatment.
4) Bacterial resistance to viomycin did not develop to a significant degree among patients treated for six months.
5) Clinical and x-ray improvement is more striking in streptomycin-PAS treated patients, however, the effectiveness of viomycin-PAS
is definite and demonstrable.
6) The clinical use of viomycin is feasible in the presence of streptomycin resistant organisms, and allergic sensitivity
to streptomycin. Its use with newer antimicrobials should be explored.</description><subject>Aminosalicylic Acid - therapeutic use</subject><subject>Antitubercular Agents</subject><subject>Old Medline</subject><subject>Sulfates</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Pulmonary - therapy</subject><subject>Viomycin - therapeutic use</subject><issn>0012-3692</issn><issn>0096-0217</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1953</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kD1PwzAYhC0EoqWwMiJPbAl2_JWMqOJLIHWgsFq26xBXTlzsBNR_j0Vheu-VHp3uDoBLjEpMRH1jOpvGsqIlL1mDj8AcNwQXhFFyDOYI4aogvKlm4CylLco_bvgpmGGCkWCMz8Hz0rvBGeXhSicbv9TowpBgGOC7C_3euAG-Tn7XqdHCrMfOwnW0auztMMLQwvWkbTSTD8mlc3DSKp_sxd9dgLf7u_XysXhZPTwtb1-KrqL1WGwQblvOsamIqChHVjeCE8axwLxqqaiVbpnhVmmRQxqqkcCE1MZsMGVUaLIA1wffXQyfU-4ve5eM9V4NNkxJCkZqzEWdwas_cNK93chddL2Ke_lfPwPlAejcR_ftopWpV95nnMjfZbdhioPyFZVc5n3JD8vDbRM</recordid><startdate>195312</startdate><enddate>195312</enddate><creator>HACKNEY, R L</creator><creator>KING, E Q</creator><creator>MARSHALL, E E</creator><creator>HARDEN, K A</creator><creator>PAYNE, H M</creator><general>American College of Chest Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>195312</creationdate><title>Clinical Observations on Viomycin Sulphate in the Treatment of Tuberculosis</title><author>HACKNEY, R L ; KING, E Q ; MARSHALL, E E ; HARDEN, K A ; PAYNE, H M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h248t-d01ff661c2372460eb97635617162f478abf5c6eab7075c4b071338ccd14547b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1953</creationdate><topic>Aminosalicylic Acid - therapeutic use</topic><topic>Antitubercular Agents</topic><topic>Old Medline</topic><topic>Sulfates</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Pulmonary - therapy</topic><topic>Viomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HACKNEY, R L</creatorcontrib><creatorcontrib>KING, E Q</creatorcontrib><creatorcontrib>MARSHALL, E E</creatorcontrib><creatorcontrib>HARDEN, K A</creatorcontrib><creatorcontrib>PAYNE, H M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HACKNEY, R L</au><au>KING, E Q</au><au>MARSHALL, E E</au><au>HARDEN, K A</au><au>PAYNE, H M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Observations on Viomycin Sulphate in the Treatment of Tuberculosis</atitle><jtitle>Chest</jtitle><addtitle>Dis Chest</addtitle><date>1953-12</date><risdate>1953</risdate><volume>24</volume><issue>6</issue><spage>591</spage><epage>600</epage><pages>591-600</pages><issn>0012-3692</issn><issn>0096-0217</issn><eissn>1931-3543</eissn><abstract>1) Viomycin in doses of 2 grams twice weekly combined with 12 grams of PAS daily is of slight toxicity.
2) Tinnitus may be expected to occur. Allergic symptoms have not been a major problem. Auditory nerve damage of a serious
degree is not frequent.
3) Streptomycin resistant organisms are affected by viomycin and patients having such organisms improve under intermittent
viomycin treatment.
4) Bacterial resistance to viomycin did not develop to a significant degree among patients treated for six months.
5) Clinical and x-ray improvement is more striking in streptomycin-PAS treated patients, however, the effectiveness of viomycin-PAS
is definite and demonstrable.
6) The clinical use of viomycin is feasible in the presence of streptomycin resistant organisms, and allergic sensitivity
to streptomycin. Its use with newer antimicrobials should be explored.</abstract><cop>United States</cop><pub>American College of Chest Physicians</pub><pmid>13107556</pmid><doi>10.1378/chest.24.6.591</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-3692 |
| ispartof | Chest, 1953-12, Vol.24 (6), p.591-600 |
| issn | 0012-3692 0096-0217 1931-3543 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75381678 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aminosalicylic Acid - therapeutic use Antitubercular Agents Old Medline Sulfates Tuberculosis Tuberculosis, Pulmonary - therapy Viomycin - therapeutic use |
| title | Clinical Observations on Viomycin Sulphate in the Treatment of Tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T02%3A09%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Observations%20on%20Viomycin%20Sulphate%20in%20the%20Treatment%20of%20Tuberculosis&rft.jtitle=Chest&rft.au=HACKNEY,%20R%20L&rft.date=1953-12&rft.volume=24&rft.issue=6&rft.spage=591&rft.epage=600&rft.pages=591-600&rft.issn=0012-3692&rft.eissn=1931-3543&rft_id=info:doi/10.1378/chest.24.6.591&rft_dat=%3Cproquest_pubme%3E75381678%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75381678&rft_id=info:pmid/13107556&rfr_iscdi=true |